Literature DB >> 15728878

Human cytomegalovirus resistance to antiviral drugs.

C Gilbert1, G Boivin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728878      PMCID： PMC549271          DOI： 10.1128/AAC.49.3.873-883.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  137 in total

1.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

Authors:  D M Forrest; E Seminari; R S Hogg; B Yip; J Raboud; L Lawson; P Phillips; M T Schechter; M V O'Shaughnessy; J S Montaner
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

2.  Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922).

Authors:  G B Mulamba; A Hu; R F Azad; K P Anderson; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus.

Authors:  K K Biron; S C Stanat; J B Sorrell; J A Fyfe; P M Keller; C U Lambe; D J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

Review 4.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

5.  Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS.

Authors:  F Baldanti; M R Underwood; S C Stanat; K K Biron; S Chou; A Sarasini; E Silini; G Gerna
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.

Authors:  M Mousavi-Jazi; L Schloss; W L Drew; A Linde; R C Miner; J Harmenberg; B Wahren; M Brytting
Journal:  J Clin Virol       Date:  2001-12       Impact factor: 3.168

7.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

Authors:  D Lowance; H H Neumayer; C M Legendre; J P Squifflet; J Kovarik; P J Brennan; D Norman; R Mendez; M R Keating; G L Coggon; A Crisp; I C Lee
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

8.  Herpes simplex virus type 1 DNA polymerase. Mutational analysis of the 3'-5'-exonuclease domain.

Authors:  F J Kühn; C W Knopf
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

Review 9.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

10.  A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.

Authors:  T Cihlar; M D Fuller; A S Mulato; J M Cherrington
Journal:  Virology       Date:  1998-09-01       Impact factor: 3.616
View more
  58 in total

Review 1.  Management of cytomegalovirus infection in solid organ transplantation.

Authors:  Camille N Kotton
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

2.  Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

3.  Characterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Martin Bisaillon
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

4.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.

Authors:  Meike Chevillotte; Ina Ersing; Thomas Mertens; Jens von Einem
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

Review 6.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

7.  Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.

Authors:  Sunwen Chou; Gail I Marousek; Laura C Van Wechel; Shaobing Li; Adriana Weinberg
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

8.  Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

Authors:  Egor P Tchesnokov; Aleksandr Obikhod; Raymond F Schinazi; Matthias Götte
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

9.  Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.

Authors:  Sunwen Chou; Gail Marousek; Shaobing Li; Adriana Weinberg
Journal:  J Clin Virol       Date:  2008-05-27       Impact factor: 3.168

10.  Novel real-time monitoring system for human cytomegalovirus-infected cells in vitro that uses a green fluorescent protein-PML-expressing cell line.

Authors:  T Ueno; Y Eizuru; H Katano; T Kurata; T Sata; S Irie; K Ogawa-Goto
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.